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Abstract 
Background: The mechanisms of the increased cardiac and vascular events in patients 
with OSA are not well understood. Arousal which is an important component of OSA 
was associated with increased sympathetic activation and electrocardiographic changes 
which prone to arrhythmias. We planned to examine the association among arousal, 
circulating Lp-PLA2 and total antioxidant capacity in male patients with OSA. 
Methods: Fifty male patients with newly diagnosed OSA were enrolled the study. A 
full-night polysomnography was performed and arousal index was obtained. Lp-PLA2 
concentrations were measured in serum samples with the PLAC Test. Total antioxidant 
capacity in patients was determined with Antioxidant Assay Kit.  
Results: Arousal was positively correlated with LP-PLA2 levels (r=0.43, p=0.002) and 
was  negatively  correlated  with  total  antioxidant  capacity  (r=  -0.29,  p=0.04).  Elevated 
LP-PLA2  levels  and  decreased  total  antioxidant  activities  were  found  in  the  highest 
arousal quartile compared with the lowest and 2nd quartiles (p=0.02, p=0.05, respec-
tively). LP-PLA2 was an independently predictor of arousal index in regression model 
(β=0.357, p=0.002)  
Conclusions: This study demonstrated a moderate linear relationship between arousal 
and  LP-PLA2  levels.  Also,  total  antioxidant  capacities  were  decreased  in  the  higher 
arousal index. Based on the study result, the patients with higher arousal index may be 
prone to vascular events. 
Key words: Obstructive sleep apnea, Arousal, Lipoprotein-associated phospholipase A2, total an-
tioxidant status, cardiovascular risk 
Introduction 
Obstructive sleep apnea (OSA) is independently 
related with increased risk for hypertension, ischemic 
stroke,  and  myocardial  ischemia  [1-3].  The  mecha-
nisms of the increased cardiac and vascular events in 
patients with OSA are not well understood. Arousal, 
in the absence of hypercapnia or  hypoxia, has been 
reported  to  be  associated  with  an  acute  increase  in 
sympathetic activity [4]. Arousals from sleep are as-
sociated with acute surges in blood pressure and heart 
rate [5-7]. The repeated arousals from sleep that occur 
in OSA  may contribute to the increased risk  of de-
veloping hypertension [1, 8], with the mediating fac-
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tor  being  the  frequent,  acute  cardiovascular  insults 
[9].  Arousal  was  also  related  with  electrocardio-
graphic  changes  at  the  RR,  QT  and  PR  intervals 
[10-12]. 
The  measurement  of  circulating  cardiovascular 
risk factors (including several novel markers of car-
diovascular disease) enables a more accurate predic-
tion of cardiovascular risk to be made, as there are 
clearly  established  relationships  between  levels  of 
various  circulating  haemostatic  risk  factors  and  a 
subsequent  cardiovascular  event  [13,  14].  In  recent 
years, several epidemiology studies have showed an 
association  among  lipoprotein-associated  phospho-
lipase A2 (Lp-PLA2), a biomarker that may be viewed 
as a potential link between noxious effects of oxidized 
LDL  cholesterol  and  elusive  plaque  vulnerability, 
cardiovascular  and  cerebrovascular  events  [15-21]. 
Increased oxidative stress and inflammation were also 
demonstrated  in  patients  with  OSA  [22].  Although, 
the  relation  between  arousal  and  cardiovascular 
changes was known, the association among circulat-
ing LP-PLA2, total antioxidant capacity and arousal 
has not been studied yet. We planned to examine the 
association  between  circulating  cardiovascular  risk 
markers and arousal in patients with OSA. 
Methods 
Patients who were referred to the Sleep labora-
tory  for  evaluation  of  sleep-disordered  breathing 
between April 2009 and January 2010 were prospec-
tively screened for the study. Fifty male patients with 
newly diagnosed OSA were enrolled to the study but 
women are not included in this study. OSA was de-
fined  as  an  apnea-hypopnea  index  (AHI)  of  ≥5  ob-
structive events per hour of sleep. The patients who 
did not meet exclusion criteria’s were consecutively 
enrolled the study. Patients with hypertension, coro-
nary artery disease, heart failure, a history of stroke, 
diabetes  mellitus,  chronic  obstructive  or  restrictive 
pulmonary  disease,  chronic  renal  disease, 
dyslipidemias, pharmacologically treated depression, 
and  tobacco  use  within  the  past  10  years  were  ex-
cluded from the study. In addition, nightshift workers 
and  patients  receiving  medications  or  nutritional 
supplements were ineligible for the study. The Selcuk 
University Ethic Committee approved the study and 
written informed consent was obtained from all study 
participants. 
Polysomnography 
At least one full-night polysomnography (PSG) 
was performed by using Compumedics E-series Sleep 
System, (Compumedics, Melbourne, Australia). Elec-
troencephalography  (EEG),  submental  electromyog-
raphy  (EMG),  leg  EMG,  electrooculography  (EOG), 
and electrocardiography (ECG) recordings were ob-
tained;  air-flow  was  measured  using  both  a  nasal 
cannula (NC) and nasal thermistor, oxygen saturation 
(SaO2)  was  measured  using  a  pulse  oximeter,  and 
chest  and  abdominal  respiratory  movements  were 
monitored. A reduction in oxygen saturation to ≤ 4 or 
the occurrence of symptoms of physiologic awaken-
ing, following at least a 30% reduction in air flow for a 
minimum  of  10  sec,  was  considered  as  hypopnea. 
Individuals with an apnea hypopnea index (AHI) >5 
were diagnosed as OSAS and included in the study.  
Determining of Arousals 
An arousal was defined as an increase in EEG 
and/or EMG activity (frequency and amplitude) that 
varies significantly from the background activity de-
fining the current sleep stage. An arousal was scored; 
during NREM sleep consisting of an abrupt EEG fre-
quency shift (eg, alpha, theta, or frequencies >16 Hz, 
but not spindles) lasting at least 3 s and accompanied 
by  at  least  10  s  of  stable  sleep.  A  REM  arousal  is 
characterized by similar EEG changes but should be 
accompanied by an increase in chin EMG that is at 
least 1 s in duration. The arousal index is the number 
of the arousals per hour of sleep [23].  
Study Protocol 
All subjects underwent attended nocturnal pol-
ysomnography  in  the  sleep  laboratory.  Nocturnal 
polysomnography was performed as previously de-
scribed. AHI was defined as the number of obstruc-
tive apnea plus hypopnea episodes per hour of sleep. 
Weight,  height,  waist  and  hip  circumference  and 
blood  pressure  of  patients  were  measured.  Other 
demographics such as diabetes mellitus, hypertension 
and smoking status were recorded. Body mass index 
was  calculated  with  formula.  The  patients  were  di-
vided into two groups according to median arousal 
index as above or below median. The demographic 
features  and  parameters  of  polysomnography  test 
were expressed as to median arousal. Venous blood 
samples were drawn into serum separator clot acti-
vator tubes at 9:00 A.M. from patients after overnight 
fasting within 48 hours of polysomnography.  
Lp-PLA2  
Lp-PLA2  concentrations  were  measured  in  se-
rum samples with the PLAC Test (diaDexus Inc, USA) 
reagent  kit  on  UniCel  DxC  800  Synchron  Clinical 
System  (Beckman  Coulter,  USA)  automated  clinical 
chemistry analyzer. The PLAC test is a turbidimetric 
immunoassay using two highly specific monoclonal 
antibodies against Lp-PLA2. Lp-PLA2 concentrations Int. J. Med. Sci. 2011, 8 
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were given as ng/ml. Clinical and analytical sensitiv-
ities of the assay are 7 ng/ml and 4 ng/ml respec-
tively.  Reference intervals suggested by the reagent 
manufacturer  are  120-342  ng/ml  for  females  and 
131-376  ng/ml  for  males.  The  assay  is  linear  up  to 
500ng/ml without prior dilution. Intra-assay and in-
ter-assay precisions are %2 and %1,6 ( Control 1: 143,9 
ng/ml) and %1,6 and %0,8 (Control 2: 449,8) respec-
tively.  The  patients  were  divided  into  four  groups 
according to arousal’s quartile. Arousal range of pa-
tients in the quartiles was defined as the lowest quar-
tile: 1.8-8.4, 2nd quartile: 8.8-14.1, 3rd quartile: 14.4-20.5, 
the highest arousal quartile: 23.6-71.6. LP-PLA2 level 
of each arousal quartile was compared. LP-PLA2 level 
of > 200 ng/ml was accepted as an elevated LP-PLA2 
[24]. 
Total Antioxidant Capacity 
Total  antioxidant  capacity  in  patients  was  de-
termined  with  Antioxidant  Assay  Kit  (Cayman 
Chemical  Company,  USA).  The  assay  relies  on  the 
ability of antioxidants in the sample to inhibit the ox-
idation of ABTS® (2,2'-azino-di-[3-ethylbenzthiazoline 
sulphonate])  to  ABTS®  ·  +  by  methmyoglobin.  The 
capacity of the antioxidants in the sample to prevent 
ABTS  oxidation  is  compared  with  that  of  Trolox,  a 
water-soluble tocopherol analogue, and is quantified 
as mM Trolox equivalents. Samples containing anti-
oxidants  between  0,044-0,330  mM  can  be  assayed 
without further dilution. Inter-assay and intra-assay 
values are %3 and %3,4 respectively 
Statistical Analysis 
Data were analyzed by using SPSS software ver-
sion  13.0  (SPSS,  Chicago,  IL,  USA)  and  were  ex-
pressed as mean ± standard deviation. The seasonal 
distribution of the variables was analyzed with Kol-
mogorov-Smirnow test. Correlation analysis was car-
ried out with Pearson’s correlation test for normally 
distributed variables. Linear regression analysis was 
performed to determine the predictors of arousal in-
dex. Firstly, linear regression analysis was performed 
with enter method and later it was performed with 
stepwise method. Independent Student’s t tests were 
used for comparing differences of parametric varia-
bles  between  two  groups.  The  difference  between 
nonparametric variables was tested by Mann Withney 
U test. Kruskal-Wallis H tests were used for compar-
ing medians of continuous variables among quartiles 
of  arousal.  When  statistically  significant  differences 
occurred,  single  posttest  comparisons  were  per-
formed by using the Mann-Whitney U test with Bon-
ferroni  correction  for  multiple  comparisons.  Differ-
ences in prevalence were tested by the nonparametric 
chi-square test. p value of < 0.05 was considered as 
statistically significant for all the tests. 
Results 
The ages of the participants were between 35-60 
years (Mean±SD was 43.5±10.5 years). Patients were 
divided  into  two  groups  according  to  the  median 
arousal value and patients’ characteristics and labor-
atory  findings  were  demonstrated  in  Table  1. 
LP-PLA2,  total  cholesterol  and  triglyceride  levels 
were increased in patients above median arousal and 
TAC  was  reduced  in  these  subjects.  Other  demo-
graphic and laboratory findings were comparable in 
two  groups.  According  to  the  arousal  quartile,  the 
level of LP-PLA2 was increased in the highest arousal 
quartile  compared  to  the  lowest  and  2nd  quartile 
(p=0.02)  (Figure  1).  Thus,  elevated  LP-PLA2  values 
were originated from the highest arousal quartile. In 
addition,  the  number  of  patients  with  elevated 
LP-PLA2 (>200 ng/ml) was increased in the highest 
arousal quartile compared to the other quartiles (n=2, 
n=2,  n=3  and  n=8,  p=0.035,  respectively  from  the 
lowest arousal quartile to the highest arousal quartile) 
(Figure 2). 
In  the  stepwise  linear  regression  model,  a 
LP-PLA2  level  was  independently  associated  with 
arousal  (p=0.002).  Linear  regression  analysis  with 
enter method demonstrated that only LP-PLA2 levels 
were related with arousal (Table 2), but hsCRP, total 
antioxidant capacity, BMI, and age were not related 
with arousal (Table 3).  
The  study  demonstrated  a  significant  negative 
correlation  between  total  antioxidant  capacity  and 
arousal (r= -0.29, p=0.04). Also, total antioxidant ca-
pacity was decreased in the group of below the me-
dian arousal index (p=0.05) (Table 1).  
Correlation analysis between LP-PLA2 and other 
variables were demonstrated in Table 4. 
 
Figure 1. It was demonstrated that LP PLA2 level was 
significantly increased in the highest arousal quartile. * 
p=0.02 Int. J. Med. Sci. 2011, 8 
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Figure 2. The distribution of patients with elevated LP PLA2 levels was demonstrated according to the arousal 
quartiles in the figure. The most of patient with elevated LP PLA2 level were clustered in the highest arousal quartile. 
*p=0.035 
 
 
Table 1. Demographic features and laboratory findings according to the median value of arousals 
 
  Below the median arousal 
(<14.25) n=25 
Above the median arousal 
(>14.25) n=25 
p 
Age  41,9±10,6  44,1±10,2  0.26 
Smoker (n)  9  14  0.35 
Hypertension (n)*  3  1  0.45 
Diabetes mellitus (n)  2  1  0.68 
BMI (kg/m2)  30,1±3,9  28,8±4,6  0.12 
Waist / hip circumference ratio  0,96±0 ,04  0,95±0,06  0.83 
Systolic Blood pressure (mmHg)  126,1±11,5  124,6±10,2  0.64 
Diastolic blood pressure (mmHg)  74,4±5,1  75,8±7,6  0.44 
LP-PLA2 (ng/ml)  152,0± 48,6 
 
217,7± 100,5  0.005 
hs-CRP (mg/dl)  3,1±3,8 
 
3,2±2,7  0.90 
TAC (mM)  1,36±0,53  1,03±0,51  0.05 
Fasting blood glucose (mg/dl)  81,3±21,8  82,7±16,3  0.79 
Total cholesterol (mg/dl)  184,0± 35,7  213,5±43,0  0,01 
Triglyceride (mg/dl)  167,0  ±76,2  247,9±175,3  0.05 
Creatinine (mg/dl)  0,92±0,12  0,92±0,11  0.83 
AHI   35,4±21,7  29,1±25,1  0.35 
Total sleep time (minute)  351,0± 62,7  330,1± 72,9  0.26 
Lowest sat O2 (%)  80,1±5,8  81,7±4,7  0.58 
hs-CRP: high sensitive C-reactive protein, BMI: Body mass index, AHI: apnea-hipopne index, TAC: Total antioxidant capacity. *Hypertension 
was defined as resting blood pressure ≥140/90 mmHg 
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Table 2. Stepwise Linear regression analysis to determine of independent predictors of the arousal index 
  B  Std. Error  Beta  t  P 
Constant  11.011  31.577    0.349  0.73 
Age  0.246  0.209  0.165  1.175  0.25 
Systolic BP (mmHg)  -0.092  0.197  -0.064  -0.464  0.65 
Apnea-hipopne index  0.151  0.092  0.231  1.638  0.11 
Total cholesterol (mg/dl)  0.036  0.075  0.099  0.488  0.63 
Triglyceride (mg/dl)  0.021  0.020  0.194  1.057  0.30 
hs-CRP  -0.038  0.664  -0.008  -0.057  0.96 
LP PLA2 (ngml)  0.063  0.028  0.357  2.226  0.03 
TAC (mM)   -3.684  3.629  -0.141  -1.015  0.32 
BMI  -0.530  0.566  -0.156  -0.936  0.36 
Dependent Variable:, R=0,59, R2=0,35, F(9,46)=2.20, P=0,04 (The first step of the stepwise linear regression model) 
Constant  3.793  4.895    0.775  0.443 
LP PLA2 (ngml)  0.077  0.024  0.437  3.259  0.002 
R= 0.44, R2=0.21, F(1,46) =10.62, P=0.002 (the last step of stepwise linear regression model) 
 
hs-CRP: high sensitive C-reactive protein, BMI: Body mass index. BP: Blood pressure, TAC: Total antioxidant capacity 
 
 
 
 
 
 
Table 3. Correlation analysis between total arousal and 
laboratory tests, demographic characteristics 
  r  p 
Age  0.12  0.38 
BMI  -0.20  0.19 
Hip/waist circumference ratio  0.08  0.57 
Systolic Blood pressure  0.07  0.65 
Diastolic blood pressure  0.10  0.47 
LP-PLA2 (ng/ml)  0.43  0.002 
TAC (mM)  -0.29 
 
0.04 
hs-CRP  0.06  0.66 
Fasting blood glucose  -0.10  0.50 
Creatinin  -0.09  0.51 
hs-CRP: high sensitive C-reactive protein, BMI: Body mass index, 
TAC: total antioxidant capacity 
 
Table 4. Correlation analysis between LP-PLA2 and 
polysomnography parameters, other laboratory findings 
  r   p 
Total arousal   0.43  0.002 
Apnea index  0.03  0.832 
Apnea-hypopnea index  -0.08  0.573 
Total sleep time  -0.27  0.06 
PLM index  0.49  0.001 
Lowest saturation (%)  0.11  0.69 
Age (years)  0.07  0.65 
BMI  -0.35  0.01 
Waist / Hip circumference ratio  -0.23  0.12 
Systolic Blood pressure (mmHg)  0.20  0.17 
Diastolic blood pressure (mmHg)  0.09  0.53 
hs-CRP (mg/dl)  0.27  0.06 
TAC (mM)  -0.17  0.24 
Fasting blood glucose (mg/dl)  -0.07  0.65 
Total cholesterol (mg/dl)  0.09  0.54 
Triglyceride (mg/dl)  0.02  0.91 
Creatinine (mg/dl)  -0.19  0.21 
hs-CRP: high sensitive C-reactive protein, BMI: Body mass index, 
PLM: Periodic Limb Movement 
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Discussion 
This study first demonstrated that arousal index 
was  positively  correlated  with  LP-PLA2  levels  and 
was negatively correlated with  total antioxidant ca-
pacity.  The  arousal  index  is  an  important  index  of 
sleep  fragmentation  and  the  restorative  quality  of 
sleep. These results may explain the increased cardi-
ovascular risk during arousal. 
Large  randomized  controlled  trials  identified 
higher circulating Lp-PLA2 levels as an independent 
predictor  for  first-time  acute  myocardial  infarction 
(AMI), cardiac death and stroke [15-18]. The Rotter-
dam study demonstrated a higher risk  of AMI and 
stroke  especially  in  patients  with  Lp-PLA2  activity 
above  the  lowest  quartile  [19].  According  to  the 
knowledge, circulating Lp-PLA2 levels were not pre-
viously studied in patients with OSA. Due to the cir-
culating  Lp-PLA2  levels,  patients  in  the  highest 
arousal quartile may have been increased risk of cor-
onary and/or cerebral event compared to the patients 
with lowest and second arousal  quartiles. Also,  the 
linear  association  between  arousal  index  and 
LP-PLA2  was  independent  from  baseline  demo-
graphic characteristics. But this relation was not valid 
to  the  total  cholesterol  and  triglyceride  levels.  So, 
Lp-PLA2 levels may be better marker of cardiovas-
cular risk in OSA especially with higher arousal in-
dex. 
Arousals  are  associated  with  acute  surges  in 
blood  pressure  and  heart  rate  [5-7].  Cardiovascular 
activity  is  closely  modulated  during  respiratory 
events; arousals show a particularly powerful effect 
on sympathetic activity in OSA patients [7, 9]. In pa-
tients  with  OSA,  the  cardiovascular  response  to  a 
postapneic arousal is two fold than to a spontaneous 
arousal  [25].  Arousal-induced  tachycardia,  which 
generally corresponds to periods of high cardiac pre- 
and  after-load  and  reduced  myocardial  oxygen  de-
livery at the termination  of respiratory events, may 
provide  a  hemodynamic  disturbance  substrate  for 
initiating cardiac event and potentially sudden cardi-
ac death. The elevated circulating LP-PLA2 levels in 
patients  with  higher  arousal  may  contribute  to  this 
hypothesis.  
Although  the  reasons  for  prevalent  nocturnal 
death in OSA remain unclear, three reasonable causes 
are  commonly  accused  by  the  investigators.  These 
factors are cardiac arrhythmias, stroke and myocar-
dial  infarction.  Firstly,  the  potential  mechanisms  of 
sudden  cardiovascular  death  in  OSA  patients  have 
been based on the cardiac electrical disturbances [10]. 
The  QT  interval,  reflecting  the  overall  duration  of 
ventricular repolarization, has been shown to be pro-
longed during apnea and suddenly shortened during 
the hyperventilation phase post apnea [11]. In healthy 
volunteers,  arousals  from  non-rapid  eye  movement 
(NREM)  sleep  consistently  produced  QT  interval 
shortening  and  PR  interval  prolongation  [12],  a  re-
sponse potentially prone to re-entry phenomena and 
consequently for arrhythmogenesis [27]. Secondly, it 
has  been  attributed  to  cardiovascular  mechanical 
stressors such as frequent apneas causing increases in 
negative  intrathoracic  pressure  and  cardiac  pre-and 
after-load  work;  and  intermittent  hypoxemia  via 
causing endothelial dysfunction [28]; and haemostatic 
disturbances  [29-31].  Finally,  the  present  study 
demonstrated that higher  arousal index was associ-
ated with increased LP-PLA2 level. The elevated lev-
els  of  circulating  LP-PLA2  may  explain  prone  to 
sudden death due stroke and AMI in patients with 
OSA and increased arousal index.  
Total antioxidant capacity 
Jelic et al. demonstrated that NO availability and 
circulating endothelial progenitor cell levels, a marker 
of endothelial repair capacity were decreased in pa-
tients with OSA compared to control subjects [22]. In 
addition, continuous positive airway pressure (CPAP) 
therapy improved these parameters [22]. The present 
study was found that there was significantly negative 
correlation  between  total  antioxidant  capacity  and 
arousal. Also, it was demonstrated that total antioxi-
dant capacity was significantly decreased in patients 
above median arousal. To knowledge, the relationship 
between  arousal  and  total  antioxidant  capacity  has 
not  been  mentioned  in  current  literature.  LP-PLA2 
level  was  related  with  vulnerable  plaque  and  de-
creasing antioxidant capacity may be additive effect 
with LP-PLA2 on cholesterol plaque. Thus, the plaque 
vulnerability to rupture has increases.  
hs-CRP  is  a  well-known  conventional  cardio-
vascular  risk  marker  and  it  was  not  related  with 
arousal index. This is the major negative result of the 
study. A possible explanation of this negative result 
that sensitivity of hs-CRP may be decrease due to the 
lower conventional risk factors of study subjects such 
as the lower percentage of patients with hypertension, 
diabetes mellitus, smoking and hypercholesterolemia. 
In addition, small number of the patients may be the 
cause of the limited difference between groups.  
Limitation  
The major limitation of the study is small num-
ber  of  the  patients  and  absence  of  a  control  group 
without OSA and this was because of limited financial 
support.  However  this  study  may  be  accepted  as a 
pilot  study.  Another  issue  is  the  exclusion  of  the Int. J. Med. Sci. 2011, 8 
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women from the study. Hormone replacement ther-
apy at the postmenopausal period affects the relation 
between  LP-PLA2  and  vascular  events  [32,  33].  In 
addition, the effect of menopause on LP-PLA2 levels 
is  unclear.  Based  on  the  current  literature,  value  of 
Lp-PLA2 in women is controversial.  
Conclusion 
Despite  these  limitations,  this  study  demon-
strated that arousal was not only associated with in-
creased  sympathetic  nervous  system  activation  and 
electrocardiographic changes but also these patients 
were  prone  to  cardiovascular  and  cerebrovascular 
events  via  elevated  levels  of  LP-PLA2,  which  is  a 
marker of increased plaque vulnerability. In addition, 
total antioxidant capacity, a marker of body defense 
system  against  increased  oxidative  stress  was  de-
creased.  These  results  need  a  confirmation  with  a 
large prospective follow up study. 
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